Form 4: Adicet Bio CEO Chen Schor Acquires 1,770,427 Stock Options

Chen Schor, President & CEO of Adicet Bio, Inc., acquired 1,770,427 stock options on June 5, 2024, at an exercise price of $2.53.

Summary

• Chen Schor, the President & CEO of Adicet Bio, Inc., filed a Form 4 on June 7, 2024, reporting a transaction.
• On June 5, 2024, Schor acquired 1,770,427 stock options with an exercise price of $2.53.
• These options vest in equal monthly installments over 48 months, starting January 26, 2024, contingent upon continued service with Adicet Bio.
• Following the transaction, Schor directly owns 1,770,427 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and aligns the CEO's interests with shareholders. There are no immediate negative implications.

Positives

• The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their executive compensation packages.
• The vesting schedule of 48 months is also fairly standard within the industry.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates